Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NP5.DE Stock Summary
In the News
NP5.DE Financial details
Company Rating
Neutral
Market Cap
0
Income
-18.91M
Revenue
6.28M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
-
P/E
-6.87
Forward P/E
0
PEG
-2.65
P/S
17.78
P/B
32.97
P/C
-
P/FCF
-
Quick Ratio
9.47
Current Ratio
10.79
Debt / Equity
-3.65
LT Debt / Equity
-3.24
-
-
EPS (TTM)
-1.06
EPS next Y
1385.87
EPS next Q
-
EPS this Y
16.67%
EPS next Y
-131151.31%
EPS next 5Y
-131151.31%
EPS last 5Y
3.13%
Revenue last 5Y
8.65%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-5.4%
SMA50
141.3%
SMA100
351.52%
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
-146%
ROC
-0.26%
Gross Margin
-
Oper. Margin
-214%
Profit Margin
-259%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.13-8.78
52W High
-28.25%
52W Low
+474%
RSI
49.98
Rel Volume
0.26
Avg Volume
11.06K
Volume
2.88K
Perf Week
-1.71%
Perf Month
-4.33%
Perf Quarter
325.19%
Perf Half Y
329.96%
-
-
-
-
Beta
-
-
-
Volatility
0.24%, 0.54%
Prev Close
0%
Price
5.74
Change
-3.04%
NP5.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.23 | 0.39 | 0.29 | 0.32 | 0.34 | |
Net income per share | -0.84 | -1.13 | -1.18 | -0.84 | -0.98 | |
Operating cash flow per share | -0.9 | -1.24 | -0.87 | -0.64 | -0.62 | |
Free cash flow per share | -0.9 | -1.25 | -0.88 | -0.64 | -0.62 | |
Cash per share | 2.46 | 2.19 | 1.75 | 1.94 | 1.28 | |
Book value per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
Tangible book value per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
Share holders equity per share | 3.07 | 2.06 | 0.97 | 0.17 | -0.79 | |
Interest debt per share | 0 | 0.98 | 1.6 | 2.58 | 2.78 | |
Market cap | 98.86M | 103.5M | 35.26M | 27.27M | 26.95M | |
Enterprise value | 71.23M | 98.34M | 48.39M | 45.33M | 59.18M | |
P/E ratio | -6.58 | -5.12 | -1.68 | -1.83 | -1.54 | |
Price to sales ratio | 24.56 | 14.71 | 6.71 | 4.73 | 4.42 | |
POCF ratio | -6.14 | -4.66 | -2.26 | -2.38 | -2.43 | |
PFCF ratio | -6.12 | -4.65 | -2.26 | -2.38 | -2.43 | |
P/B Ratio | 1.8 | 2.81 | 2.04 | 8.78 | -1.92 | |
PTB ratio | 1.8 | 2.81 | 2.04 | 8.78 | -1.92 | |
EV to sales | 17.7 | 13.97 | 9.2 | 7.87 | 9.71 | |
Enterprise value over EBITDA | -4.78 | -5.07 | -2.82 | -3.86 | -4.44 | |
EV to operating cash flow | -4.42 | -4.43 | -3.1 | -3.96 | -5.34 | |
EV to free cash flow | -4.41 | -4.42 | -3.1 | -3.95 | -5.33 | |
Earnings yield | -0.15 | -0.2 | -0.6 | -0.55 | -0.65 | |
Free cash flow yield | -0.16 | -0.22 | -0.44 | -0.42 | -0.41 | |
Debt to equity | 0.09 | 0.64 | 1.97 | 15.25 | -3.65 | |
Debt to assets | 0.08 | 0.39 | 0.66 | 0.94 | 1.38 | |
Net debt to EBITDA | 1.85 | 0.27 | -0.77 | -1.54 | -2.42 | |
Current ratio | 13.9 | 10.71 | 5.5 | 10.79 | 5.65 | |
Interest coverage | -267.46 | -36.54 | -8.07 | -4.23 | -3.37 | |
Income quality | 1.07 | 1.1 | 0.74 | 0.77 | 0.63 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.28 | 0.91 | 0.94 | 0.61 | 0.58 | |
Research and developement to revenue | 1.23 | 1.71 | 1.97 | 1.86 | 1.97 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.85 | -0.25 | -0.16 | -0.1 | -0.09 | |
Stock based compensation to revenue | 0.52 | 0.3 | 0.28 | 0.13 | 0.08 | |
Graham number | 7.63 | 7.25 | 5.06 | 1.81 | 4.16 | |
ROIC | -4.49 | -1.52 | -0.82 | 11.73 | -1.58 | |
Return on tangible assets | -0.25 | -0.34 | -0.41 | -0.3 | -0.47 | |
Graham Net | 2.18 | 0.88 | -0.15 | -0.72 | -1.59 | |
Working capital | 55.23M | 54.35M | 30.98M | 35.77M | 23.45M | |
Tangible asset value | 54.81M | 36.8M | 17.25M | 3.11M | -14.03M | |
Net current asset value | 54.63M | 36.46M | 3.92M | -7.95M | -22.73M | |
Invested capital | 0 | 0.46 | 1.53 | 13.87 | -3.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.69M | 1.78M | 1.84M | 1.39M | 1.71M | |
Average inventory | 2.5K | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 305.67 | 616.27 | 1.58K | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 1.19 | 0.59 | 0.23 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.27 | -0.55 | -1.22 | -4.8 | 1.25 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2020-12-31 | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | 13.13M | 15.55M | 18.06M | 25.58M | 32.24M | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 1.97 | 3.59 | 15.25 | -9.3 | -3.65 | |
Debt to assets | 0.66 | 0.78 | 0.94 | 1.12 | 1.38 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 5.5 | 7.9 | 10.79 | 8.84 | 5.65 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 30.98M | 24.34M | 35.77M | 29.98M | 23.45M | |
Tangible asset value | 17.25M | 8.69M | 3.11M | -5.25M | -14.03M | |
Net current asset value | 3.92M | -3.32M | -7.95M | -14.98M | -22.73M | |
Invested capital | 1.53 | 3.1 | 13.87 | -8.48 | -3.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NP5.DE Frequently Asked Questions
What is Newron Pharmaceuticals SpA stock symbol ?
Newron Pharmaceuticals SpA is a IT stock , located in Bresso of Milano and trading under the symbol NP5.DE
What is Newron Pharmaceuticals SpA stock quote today ?
Newron Pharmaceuticals SpA stock price is $5.74 today.
Is Newron Pharmaceuticals SpA stock public?
Yes, Newron Pharmaceuticals SpA is a publicly traded company.